AMLN

Q2: Second Verse, Just Like the First — Monday’s IP Market Recap

Second-quarter trading picks up where Q1 left off -- by advancing smartly on the first day of trading. More 

Here Comes a Bidding War for Amylin

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More 

Amylin Perks Up on Rejection — Wednesday’s IP Market Recap

A spurned bid from Bristol-Myers Squibb sends AMLN up 54% on speculation that other offers will roll in. More 

‘Spam’ Linked to Diabetes in Native Americans

A new study raises questions about processed meat intake among Native Americans living on reservations and the development of diabetes. More